Mechanism

How it works

AICAR is taken up by cells and phosphorylated to ZMP (AICA ribonucleotide monophosphate), which directly activates AMP-activated protein kinase (AMPK) by mimicking AMP accumulation — the cell's primary signal of energy depletion. Activated AMPK switches on catabolic pathways (fatty acid oxidation, glycolysis) and suppresses anabolic energy-consuming processes, while also stimulating GLUT4 translocation and upregulating PGC-1α to drive mitochondrial biogenesis. This effectively induces many of the molecular adaptations associated with endurance exercise at the gene expression level.

Reported in research

Benefits

Activates AMPK to enhance fatty acid oxidation and metabolic flexibility without exercise
Promotes mitochondrial biogenesis via PGC-1α upregulation, increasing cellular energy efficiency
Improves insulin sensitivity and glucose uptake through GLUT4 translocation
Demonstrated endurance enhancement in rodent models equivalent to weeks of aerobic training

Context, not a prescription

Dosing

Typical range: 500 mg/day (research protocols); some human-use reports cite 250–500 mg/day (Subcutaneous, Intramuscular)
Cycle length: 4–8 weeks
Half-life: ~4–6 hours

Safety

Side effects & contraindications

Possible side effects

Hypoglycemia risk, particularly when combined with insulin or other glucose-lowering agents
Nausea and gastrointestinal discomfort at higher doses
Potential pro-growth signaling concerns in cells with existing oncogenic mutations (theoretical)
Lactic acidosis risk at supraphysiological doses (animal data)
Fatigue or lightheadedness due to acute glucose fluctuations

Contraindications

Active malignancy or history of cancer — AMPK signaling has complex roles in tumor biology
Type 1 diabetes or insulin-dependent diabetes without careful glucose monitoring
Concurrent use of metformin or other AMPK-activating agents (additive hypoglycemia risk)
Pregnancy and breastfeeding — no safety data available

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Users commonly report improved stamina during cardiovascular exercise, reduced body fat — especially around the midsection — improved recovery between sessions, and better blood sugar control after meals.

How it works

Think of AMPK like a thermostat that kicks on when your body senses it's running low on energy. AICAR fools the thermostat into thinking you've just run a marathon, so your body responds by becoming more efficient at burning fuel — even when you're sitting still.

After injection, AICAR is absorbed and converted into a molecule that tricks your cells into activating their energy-management system. This causes your muscles to absorb more sugar from the blood, burn more fat, and gradually build more mitochondria — the tiny power plants inside your cells.

What to expect

Some metabolic effects (such as glucose uptake changes) can begin within hours of dosing. Noticeable endurance or body composition changes typically emerge after 2–4 weeks of consistent use.

Week 1: Early metabolic adaptation begins; some users notice slightly better energy levels and mild appetite changes. Watch for blood sugar dips.
Weeks 2-4: Improved cardiovascular endurance starts to emerge; fat oxidation increases; some users notice improved blood sugar stability after meals.
Weeks 4-8: Cumulative mitochondrial adaptations become noticeable — more sustained energy, visible body composition improvements, and enhanced workout capacity.

Good to know

Always eat a balanced meal before dosing to prevent low blood sugar episodes
Start with a lower dose (250 mg) and monitor how your body responds before increasing

Staying safe

Low blood sugar (feeling shaky, dizzy, or hungry) especially if you skip meals
Mild nausea, particularly when first starting

Avoid if you have:

People with diabetes who use insulin — risk of dangerous low blood sugar
People with a personal or family history of cancer — consult a physician first

Overview

Chronic AICAR administration in rodents produces a ~44% increase in running endurance (Narkar et al., 2008, Cell). Human metabolic studies show improvements in insulin-stimulated glucose disposal, reduced fasting triglycerides, and upregulation of skeletal muscle oxidative gene expression (PGC-1α, CPT1, GLUT4 mRNA). Structural remodeling includes increased mitochondrial density by electron microscopy in animal models. Body composition changes in human studies are less well-characterized but consistent with enhanced fat oxidation.

How it works

AICAR is like submitting a fraudulent energy bankruptcy filing to the cell's regulatory authority (AMPK). The cell's AMPK 'auditor' reads the ZMP molecule as evidence of AMP accumulation — an energy crisis — and triggers an emergency restructuring program: cutting anabolic spending (protein synthesis, lipogenesis via mTOR/ACC suppression) and maximizing catabolic revenue generation (β-oxidation, glycolysis, mitochondrial biogenesis). The cell acts as if it's training under energy stress even in the absence of mechanical work.

Following subcutaneous or intravenous administration, AICAR exhibits rapid cellular uptake via equilibrative nucleoside transporters (ENT1/2). Intracellular phosphorylation to ZMP occurs within minutes; ZMP accumulates to millimolar concentrations sufficient to activate AMPK heterotrimers (α1β1γ1, α2β2γ1, and other isoform combinations) in a tissue-selective manner. Skeletal muscle, liver, and cardiac tissue show prominent AMPK activation. Hepatic AMPK activation suppresses SREBP-1c and ChREBP, reducing de novo lipogenesis and improving hepatic insulin signaling. In skeletal muscle, AICAR-driven AMPK phosphorylates PGC-1α at Thr177 and Ser538, synergizing with SIRT1 deacetylation to transactivate genes encoding OXPHOS components (CYTC, ATP synthase subunits, COXI).

Onset & timeline

ZMP accumulation and measurable AMPK phosphorylation occur within 30–60 minutes of administration in rodent models. In human clinical contexts, acute metabolic effects (suppressed lipid synthesis, enhanced fatty acid oxidation markers) have been demonstrated within 2–4 hours. Meaningful mitochondrial biogenesis and phenotypic endurance adaptations require sustained activation over multiple weeks.

Days 1-3: ZMP accumulation reaches steady-state intracellular concentrations; ACC phosphorylation (Ser79) measurably elevated; early suppression of hepatic lipogenesis detectable. Blood glucose monitoring recommended.
Weeks 1-2: PGC-1α transcriptional program initiating — upregulation of NRF1, TFAM, and mitochondrial-encoded genes. GLUT4 protein expression begins increasing in skeletal muscle. Subjective improvements in aerobic efficiency may emerge.
Weeks 2-8: Cumulative mitochondrial biogenesis reaches a new setpoint — increased mitochondrial density, enhanced VO2 utilization efficiency, improved lipid oxidation rate. Insulin sensitivity improvements measurable by HOMA-IR. Peak endurance adaptations plateauing by week 6-8.

Getting the most from it

Monitor fasting and postprandial glucose during the first 2 weeks of use; consider continuous glucose monitoring (CGM) for individuals with metabolic conditions
Avoid co-administration with other AMPK activators (metformin, berberine, phenformin) to prevent additive hypoglycemia and potential lactic acidosis
Cycle with structured on/off periods (e.g., 6 weeks on, 4 weeks off) to avoid chronic AMPK hyperactivation and potential downregulation of counter-regulatory anabolic signaling

Common side effects

Hypoglycemia: AICAR-driven GLUT4 translocation and glycogenolysis suppression can reduce blood glucose by 10–20% in fasted states; clinically relevant in diabetic or caloric-restricted individuals
Transient nausea attributed to rapid metabolic flux changes, particularly at doses >500 mg
Uric acid elevation: ZMP metabolism produces AMP breakdown products including uric acid, potentially relevant in gout-susceptible individuals

Mechanism of action

AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) is transported into cells via adenosine transporters and phosphorylated by adenosine kinase to form ZMP (AICA ribonucleotide monophosphate). ZMP is a structural analog of AMP that allosterically activates AMPK by binding to the γ-subunit's CBS domain, mimicking a high AMP:ATP ratio without actually depleting cellular ATP. Activated AMPK (pAMPK-Thr172) phosphorylates downstream substrates including ACC (acetyl-CoA carboxylase), reducing malonyl-CoA and disinhibiting CPT1 to enhance mitochondrial fatty acid import and β-oxidation. Simultaneously, AMPK activates PGC-1α (via SIRT1-mediated deacetylation and direct phosphorylation), driving NRF1/TFAM-mediated mitochondrial biogenesis. AMPK also stimulates GLUT4 vesicle translocation to the plasma membrane independent of insulin signaling through AS160 (TBC1D4) phosphorylation, improving skeletal muscle glucose uptake. Additionally, AICAR suppresses mTORC1 via TSC2 phosphorylation and Raptor phosphorylation, inhibiting protein synthesis under low-energy conditions.

Following subcutaneous or intravenous administration, AICAR exhibits rapid cellular uptake via equilibrative nucleoside transporters (ENT1/2). Intracellular phosphorylation to ZMP occurs within minutes; ZMP accumulates to millimolar concentrations sufficient to activate AMPK heterotrimers (α1β1γ1, α2β2γ1, and other isoform combinations) in a tissue-selective manner. Skeletal muscle, liver, and cardiac tissue show prominent AMPK activation. Hepatic AMPK activation suppresses SREBP-1c and ChREBP, reducing de novo lipogenesis and improving hepatic insulin signaling. In skeletal muscle, AICAR-driven AMPK phosphorylates PGC-1α at Thr177 and Ser538, synergizing with SIRT1 deacetylation to transactivate genes encoding OXPHOS components (CYTC, ATP synthase subunits, COXI).

Pharmacodynamics

ZMP accumulation and measurable AMPK phosphorylation occur within 30–60 minutes of administration in rodent models. In human clinical contexts, acute metabolic effects (suppressed lipid synthesis, enhanced fatty acid oxidation markers) have been demonstrated within 2–4 hours. Meaningful mitochondrial biogenesis and phenotypic endurance adaptations require sustained activation over multiple weeks.

Chronic AICAR administration in rodents produces a ~44% increase in running endurance (Narkar et al., 2008, Cell). Human metabolic studies show improvements in insulin-stimulated glucose disposal, reduced fasting triglycerides, and upregulation of skeletal muscle oxidative gene expression (PGC-1α, CPT1, GLUT4 mRNA). Structural remodeling includes increased mitochondrial density by electron microscopy in animal models. Body composition changes in human studies are less well-characterized but consistent with enhanced fat oxidation.

Timeline

Days 1-3: ZMP accumulation reaches steady-state intracellular concentrations; ACC phosphorylation (Ser79) measurably elevated; early suppression of hepatic lipogenesis detectable. Blood glucose monitoring recommended.
Weeks 1-2: PGC-1α transcriptional program initiating — upregulation of NRF1, TFAM, and mitochondrial-encoded genes. GLUT4 protein expression begins increasing in skeletal muscle. Subjective improvements in aerobic efficiency may emerge.
Weeks 2-8: Cumulative mitochondrial biogenesis reaches a new setpoint — increased mitochondrial density, enhanced VO2 utilization efficiency, improved lipid oxidation rate. Insulin sensitivity improvements measurable by HOMA-IR. Peak endurance adaptations plateauing by week 6-8.

Comparisons

AICAR — effectiveness High, safety Moderate, cost $$, Medium to use
Cardarine (GW501516) — effectiveness High, safety Caution, cost $$, Medium to use

Adverse effects

Common:

Hypoglycemia: AICAR-driven GLUT4 translocation and glycogenolysis suppression can reduce blood glucose by 10–20% in fasted states; clinically relevant in diabetic or caloric-restricted individuals
Transient nausea attributed to rapid metabolic flux changes, particularly at doses >500 mg
Uric acid elevation: ZMP metabolism produces AMP breakdown products including uric acid, potentially relevant in gout-susceptible individuals

Rare:

Lactic acidosis: Theoretically possible at supraphysiological doses due to enhanced glycolytic flux and mitochondrial electron transport chain uncoupling; predominantly observed in animal overdose models
Pro-tumorigenic signaling: AMPK has context-dependent roles in cancer biology — while generally tumor-suppressive via mTOR inhibition, AMPK can support cancer cell survival under metabolic stress; risk is theoretical in humans but warrants caution

Contraindications & risk mitigation

Contraindicated in:

Individuals with hematologic malignancies — acadesine has been studied as a pro-apoptotic agent in CLL, indicating significant biological activity in lymphoid tissue
Patients on sulfonylureas, insulin, or GLP-1 agonists — additive hypoglycemic risk
Individuals with xanthinuria or gout — increased purine catabolism may exacerbate uric acid burden
Patients with mitochondrial disorders — unpredictable effects on electron transport chain function

Monitor fasting and postprandial glucose during the first 2 weeks of use; consider continuous glucose monitoring (CGM) for individuals with metabolic conditions
Avoid co-administration with other AMPK activators (metformin, berberine, phenformin) to prevent additive hypoglycemia and potential lactic acidosis
Cycle with structured on/off periods (e.g., 6 weeks on, 4 weeks off) to avoid chronic AMPK hyperactivation and potential downregulation of counter-regulatory anabolic signaling

Qué hace

Users commonly report improved stamina during cardiovascular exercise, reduced body fat — especially around the midsection — improved recovery between sessions, and better blood sugar control after meals.

Cómo funciona

Think of AMPK like a thermostat that kicks on when your body senses it's running low on energy. AICAR fools the thermostat into thinking you've just run a marathon, so your body responds by becoming more efficient at burning fuel — even when you're sitting still.

After injection, AICAR is absorbed and converted into a molecule that tricks your cells into activating their energy-management system. This causes your muscles to absorb more sugar from the blood, burn more fat, and gradually build more mitochondria — the tiny power plants inside your cells.

Qué esperar

Some metabolic effects (such as glucose uptake changes) can begin within hours of dosing. Noticeable endurance or body composition changes typically emerge after 2–4 weeks of consistent use.

Week 1: Early metabolic adaptation begins; some users notice slightly better energy levels and mild appetite changes. Watch for blood sugar dips.
Weeks 2-4: Improved cardiovascular endurance starts to emerge; fat oxidation increases; some users notice improved blood sugar stability after meals.
Weeks 4-8: Cumulative mitochondrial adaptations become noticeable — more sustained energy, visible body composition improvements, and enhanced workout capacity.

Bueno saber

Always eat a balanced meal before dosing to prevent low blood sugar episodes
Start with a lower dose (250 mg) and monitor how your body responds before increasing

Manteniéndose seguro

Low blood sugar (feeling shaky, dizzy, or hungry) especially if you skip meals
Mild nausea, particularly when first starting

Evitar si tienes:

People with diabetes who use insulin — risk of dangerous low blood sugar
People with a personal or family history of cancer — consult a physician first

Descripción general

Chronic AICAR administration in rodents produces a ~44% increase in running endurance (Narkar et al., 2008, Cell). Human metabolic studies show improvements in insulin-stimulated glucose disposal, reduced fasting triglycerides, and upregulation of skeletal muscle oxidative gene expression (PGC-1α, CPT1, GLUT4 mRNA). Structural remodeling includes increased mitochondrial density by electron microscopy in animal models. Body composition changes in human studies are less well-characterized but consistent with enhanced fat oxidation.

Cómo funciona

AICAR is like submitting a fraudulent energy bankruptcy filing to the cell's regulatory authority (AMPK). The cell's AMPK 'auditor' reads the ZMP molecule as evidence of AMP accumulation — an energy crisis — and triggers an emergency restructuring program: cutting anabolic spending (protein synthesis, lipogenesis via mTOR/ACC suppression) and maximizing catabolic revenue generation (β-oxidation, glycolysis, mitochondrial biogenesis). The cell acts as if it's training under energy stress even in the absence of mechanical work.

Following subcutaneous or intravenous administration, AICAR exhibits rapid cellular uptake via equilibrative nucleoside transporters (ENT1/2). Intracellular phosphorylation to ZMP occurs within minutes; ZMP accumulates to millimolar concentrations sufficient to activate AMPK heterotrimers (α1β1γ1, α2β2γ1, and other isoform combinations) in a tissue-selective manner. Skeletal muscle, liver, and cardiac tissue show prominent AMPK activation. Hepatic AMPK activation suppresses SREBP-1c and ChREBP, reducing de novo lipogenesis and improving hepatic insulin signaling. In skeletal muscle, AICAR-driven AMPK phosphorylates PGC-1α at Thr177 and Ser538, synergizing with SIRT1 deacetylation to transactivate genes encoding OXPHOS components (CYTC, ATP synthase subunits, COXI).

Inicio y cronología

ZMP accumulation and measurable AMPK phosphorylation occur within 30–60 minutes of administration in rodent models. In human clinical contexts, acute metabolic effects (suppressed lipid synthesis, enhanced fatty acid oxidation markers) have been demonstrated within 2–4 hours. Meaningful mitochondrial biogenesis and phenotypic endurance adaptations require sustained activation over multiple weeks.

Days 1-3: ZMP accumulation reaches steady-state intracellular concentrations; ACC phosphorylation (Ser79) measurably elevated; early suppression of hepatic lipogenesis detectable. Blood glucose monitoring recommended.
Weeks 1-2: PGC-1α transcriptional program initiating — upregulation of NRF1, TFAM, and mitochondrial-encoded genes. GLUT4 protein expression begins increasing in skeletal muscle. Subjective improvements in aerobic efficiency may emerge.
Weeks 2-8: Cumulative mitochondrial biogenesis reaches a new setpoint — increased mitochondrial density, enhanced VO2 utilization efficiency, improved lipid oxidation rate. Insulin sensitivity improvements measurable by HOMA-IR. Peak endurance adaptations plateauing by week 6-8.

Cómo aprovecharlo al máximo

Monitor fasting and postprandial glucose during the first 2 weeks of use; consider continuous glucose monitoring (CGM) for individuals with metabolic conditions
Avoid co-administration with other AMPK activators (metformin, berberine, phenformin) to prevent additive hypoglycemia and potential lactic acidosis
Cycle with structured on/off periods (e.g., 6 weeks on, 4 weeks off) to avoid chronic AMPK hyperactivation and potential downregulation of counter-regulatory anabolic signaling

Efectos secundarios comunes

Hypoglycemia: AICAR-driven GLUT4 translocation and glycogenolysis suppression can reduce blood glucose by 10–20% in fasted states; clinically relevant in diabetic or caloric-restricted individuals
Transient nausea attributed to rapid metabolic flux changes, particularly at doses >500 mg
Uric acid elevation: ZMP metabolism produces AMP breakdown products including uric acid, potentially relevant in gout-susceptible individuals

Mecanismo de acción

AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) is transported into cells via adenosine transporters and phosphorylated by adenosine kinase to form ZMP (AICA ribonucleotide monophosphate). ZMP is a structural analog of AMP that allosterically activates AMPK by binding to the γ-subunit's CBS domain, mimicking a high AMP:ATP ratio without actually depleting cellular ATP. Activated AMPK (pAMPK-Thr172) phosphorylates downstream substrates including ACC (acetyl-CoA carboxylase), reducing malonyl-CoA and disinhibiting CPT1 to enhance mitochondrial fatty acid import and β-oxidation. Simultaneously, AMPK activates PGC-1α (via SIRT1-mediated deacetylation and direct phosphorylation), driving NRF1/TFAM-mediated mitochondrial biogenesis. AMPK also stimulates GLUT4 vesicle translocation to the plasma membrane independent of insulin signaling through AS160 (TBC1D4) phosphorylation, improving skeletal muscle glucose uptake. Additionally, AICAR suppresses mTORC1 via TSC2 phosphorylation and Raptor phosphorylation, inhibiting protein synthesis under low-energy conditions.

Following subcutaneous or intravenous administration, AICAR exhibits rapid cellular uptake via equilibrative nucleoside transporters (ENT1/2). Intracellular phosphorylation to ZMP occurs within minutes; ZMP accumulates to millimolar concentrations sufficient to activate AMPK heterotrimers (α1β1γ1, α2β2γ1, and other isoform combinations) in a tissue-selective manner. Skeletal muscle, liver, and cardiac tissue show prominent AMPK activation. Hepatic AMPK activation suppresses SREBP-1c and ChREBP, reducing de novo lipogenesis and improving hepatic insulin signaling. In skeletal muscle, AICAR-driven AMPK phosphorylates PGC-1α at Thr177 and Ser538, synergizing with SIRT1 deacetylation to transactivate genes encoding OXPHOS components (CYTC, ATP synthase subunits, COXI).

Farmacodinamia

ZMP accumulation and measurable AMPK phosphorylation occur within 30–60 minutes of administration in rodent models. In human clinical contexts, acute metabolic effects (suppressed lipid synthesis, enhanced fatty acid oxidation markers) have been demonstrated within 2–4 hours. Meaningful mitochondrial biogenesis and phenotypic endurance adaptations require sustained activation over multiple weeks.

Chronic AICAR administration in rodents produces a ~44% increase in running endurance (Narkar et al., 2008, Cell). Human metabolic studies show improvements in insulin-stimulated glucose disposal, reduced fasting triglycerides, and upregulation of skeletal muscle oxidative gene expression (PGC-1α, CPT1, GLUT4 mRNA). Structural remodeling includes increased mitochondrial density by electron microscopy in animal models. Body composition changes in human studies are less well-characterized but consistent with enhanced fat oxidation.

Cronología

Days 1-3: ZMP accumulation reaches steady-state intracellular concentrations; ACC phosphorylation (Ser79) measurably elevated; early suppression of hepatic lipogenesis detectable. Blood glucose monitoring recommended.
Weeks 1-2: PGC-1α transcriptional program initiating — upregulation of NRF1, TFAM, and mitochondrial-encoded genes. GLUT4 protein expression begins increasing in skeletal muscle. Subjective improvements in aerobic efficiency may emerge.
Weeks 2-8: Cumulative mitochondrial biogenesis reaches a new setpoint — increased mitochondrial density, enhanced VO2 utilization efficiency, improved lipid oxidation rate. Insulin sensitivity improvements measurable by HOMA-IR. Peak endurance adaptations plateauing by week 6-8.

Comparaciones

AICAR — efectividad High, seguridad Moderate, costo $$, Medium de usar
Cardarine (GW501516) — efectividad High, seguridad Caution, costo $$, Medium de usar

Efectos adversos

Comunes:

Hypoglycemia: AICAR-driven GLUT4 translocation and glycogenolysis suppression can reduce blood glucose by 10–20% in fasted states; clinically relevant in diabetic or caloric-restricted individuals
Transient nausea attributed to rapid metabolic flux changes, particularly at doses >500 mg
Uric acid elevation: ZMP metabolism produces AMP breakdown products including uric acid, potentially relevant in gout-susceptible individuals

Raros:

Lactic acidosis: Theoretically possible at supraphysiological doses due to enhanced glycolytic flux and mitochondrial electron transport chain uncoupling; predominantly observed in animal overdose models
Pro-tumorigenic signaling: AMPK has context-dependent roles in cancer biology — while generally tumor-suppressive via mTOR inhibition, AMPK can support cancer cell survival under metabolic stress; risk is theoretical in humans but warrants caution

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with hematologic malignancies — acadesine has been studied as a pro-apoptotic agent in CLL, indicating significant biological activity in lymphoid tissue
Patients on sulfonylureas, insulin, or GLP-1 agonists — additive hypoglycemic risk
Individuals with xanthinuria or gout — increased purine catabolism may exacerbate uric acid burden
Patients with mitochondrial disorders — unpredictable effects on electron transport chain function

Monitor fasting and postprandial glucose during the first 2 weeks of use; consider continuous glucose monitoring (CGM) for individuals with metabolic conditions
Avoid co-administration with other AMPK activators (metformin, berberine, phenformin) to prevent additive hypoglycemia and potential lactic acidosis
Cycle with structured on/off periods (e.g., 6 weeks on, 4 weeks off) to avoid chronic AMPK hyperactivation and potential downregulation of counter-regulatory anabolic signaling

Reference data

Specifications

Molecular formula: C9H14N4O5
Molecular weight: 258.23 g/mol
Half-life: ~4–6 hours
Route: Subcutaneous, Intramuscular
Cycle length: 4–8 weeks
Storage: Store lyophilized powder at -20°C protected from light. Reconstituted solution should be stored at 4°C and used within 7–14 days. Avoid repeated freeze-thaw cycles.
Legal status: Not approved by the FDA for human use; classified as a research chemical. Prohibited by WADA in competitive sports as a metabolic modulator. Legal to purchase for research purposes in many jurisdictions.

FAQ

Common questions

How does AICAR compare mechanistically to metformin as an AMPK activator?

Metformin activates AMPK indirectly by inhibiting mitochondrial Complex I, thereby increasing the cellular AMP:ATP ratio authentically. AICAR, by contrast, directly provides ZMP as an AMP mimetic without altering the actual adenylate energy charge. This means AICAR can activate AMPK even in metabolically replete cells — a mechanistic distinction that makes AICAR a more 'direct' activator and useful research tool for delineating AMPK-specific effects. However, the direct ZMP mechanism also bypasses some of the safety controls that limit metformin's AMPK activation to genuinely energy-stressed states.

What is the evidence for AICAR-induced endurance enhancement in humans?

The landmark Narkar et al. (2008, Cell 134:405-415) study demonstrated a 44% increase in running endurance in sedentary mice treated with AICAR alone, establishing the 'exercise in a pill' concept. Human data is much more limited — clinical trials have primarily evaluated AICAR (acadesine) as a cardioprotective agent during cardiac surgery and as an anti-cancer agent in CLL, rather than for performance enhancement. Metabolic studies have confirmed AMPK activation and acute improvements in insulin sensitivity in humans, but endurance enhancement data in humans remains largely extrapolated from preclinical work.

What is the evidence level?

This compound is classified as Limited human data. Some human data exists but trials are small, short-term, or not yet replicated.

Research

Research & sources

Limited human

Current evidence for AICAR is rated as Limited human data. Limited human data is available.

1. AMPK and PPARδ agonists are exercise mimetics (2008) — Cell, 134(3):405-415. doi:10.1016/j.cell.2008.06.051
2. AICAR inhibits adipocyte differentiation in 3T3L1 and restores metabolic alterations in diet-induced obesity mice model (2016) — Nutrition & Metabolism, 13:27. doi:10.1186/s12986-016-0086-3
3. Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death (2009) — PLOS ONE, 4(11):e7889
4. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function (2012) — Genes & Development, 26(17):1893-1908. doi:10.1101/gad.183756.111

Explore

Often discussed alongside

TB-500 · healing BPC-157 · healing